Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study
Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study. // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000392?dgcid=rss_sd_all
Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study. International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000392?dgcid=rss_sd_all
“Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study.” International Journal of Lung Cancer.
@article{article100399,
title = {Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000392?dgcid=rss_sd_all}
}